Bortezomib 3,5 mg | Laboratorio Chile | Teva
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Biomolecules | Free Full-Text | Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations | HTML
Bortezomib-Teva®
Bortezomib Teva 3.5 mg | Medic
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Download bortezomib images for free
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma | Leukemia
With appeals court win, Takeda scores blockbuster Velcade patent reprieve till 2022 | Fierce Pharma
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Bortez Teva | Medic
Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis
Summary Public Assessment Report Generics Bortezomib Teva 1 mg and 3.5 mg powder for solution for injection Bortezomib HR/H/0102
View of Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored at 4°C and Room Temperature (23°C or 25°C) | Canadian Journal of Hospital Pharmacy
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Bortez Teva 3.5mg ג"מ 3.5 בורטז טבע אבקה להכת תמיסה להזרקה Powder for solution for injectio
PRODUCT CATALOGUE
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
